AMBU B Ambu A/S Class B

AMBU APPOINTS NEW CHIEF FINANCIAL OFFICER

AMBU APPOINTS NEW CHIEF FINANCIAL OFFICER

Thomas Frederik Schmidt will step down as CFO of Ambu by 31 December 2023; Henrik Skak Bender named as new CFO, effective 1 January 2024.



Ambu A/S has appointed Henrik Skak Bender as the company’s new Chief Financial Officer and member of the Executive Management, effective 1 January 2024. Henrik succeeds Thomas Frederik Schmidt, who will step down, effective 31 December 2023.



During Thomas’ period as CFO, the financial situation of Ambu has stabilised, the company has returned to positive free cash flow ahead of plan and reduced its gearing to a low level, and first steps have been taken towards strong profitable growth. During the next phase of the strategy, Ambu will zoom in on accelerating growth, while delivering improved profitability. Henrik Skak Bender will take on the CFO leadership during this phase, leveraging his strategic and operational experience from international companies to drive efficiency, agility and growth.



"In the progression of Ambu’s ZOOM IN strategy, I have, together with the Board, decided to bring in a new leadership profile to execute on the next phase of Ambu’s transformation and growth journey. I am convinced that Henrik is the right profile for the CFO role at Ambu, as he brings strategic and operational experience from global companies, as well as the medical device industry. On behalf of myself and the Board, I want to thank Thomas for his contributions to Ambu, and I wish him the best for the future."

BRITT MEELBY JENSEN

Chief Executive Officer at Ambu



STRONG PROFILE WITHIN MEDICAL DEVICES AND GROWTH TRANSFORMATIONS


During the past 20 years, Henrik has worked at leading international companies, such as WS Audiology, Urban Partners, McKinsey & Co and A.P. Moller-Maersk. At the hearing aid company, WS Audiology, he served as CFO and Head of Integration, leading the finance, IT, legal and procurement functions. Prior to that, he served as CFO at Widex, where he was responsible for developing and executing the company’s growth and transformation strategy, together with the rest of the management team.



Most recently, Henrik joins from the asset management company, Urban Partners, where he serves as a member of the executive management, leading the company to grow from a Nordic player with EUR 6bn in assets under management in 2020 to a Northern European player with EUR +20bn in assets under management. At Urban Partners, Henrik held a position as Partner and COO, where he focused on driving and scaling a wide range of functions, including Investor Relations, Finance, IT and Sustainability.



With his entry into Ambu, Henrik is looking forward to returning to the medical devices industry and to making an impact on the company’s growth and transformation journey:



"I am very excited to join Ambu at such a pivotal time in the company’s transformation journey, playing my part in unlocking Ambu’s significant potential. Throughout my career, my drive has been to create sustainable long-term impact by building and leading high-performing teams of people who want to make a real difference. I am looking forward to working with my future Ambu colleagues to deliver on the strategy, as well as engaging with analysts, investors and partners to drive strong long-term stakeholder and shareholder value."

HENRIK SKAK BENDER

Upcoming Chief Financial Officer at Ambu, as of 1 January 2024









Ambu A/S

Baltorpbakken 13

2750 Ballerup

Denmark

Tel.

CVR no.: 63 64 49 19



CONTACT

Investors

Anders Hjort

Head of Investor Relations







Media

Tine Bjørn Schmidt

Head of Corporate Communications



ABOUT AMBU

Ever since 1937, Ambu has been rethinking medical solutions to save lives and improve patient care. Millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring solutions. Today, we continue to collaborate with leading medical experts to deliver innovations that make a real difference to healthcare professionals and their patients. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, Latin America and the Asia Pacific, 4,500 team members keep Ambu moving forward. For more information, please visit Ambu.com.

Attachment



EN
11/10/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ambu A/S Class B

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Jesper Ingildsen
  • Jesper Ingildsen

Ambu (Buy, TP: DKK144.00) - Possibly isolated softness

Q2 was below our forecast, but the softness might be isolated to Q2 on what could be Chinese competitors dumping stock ahead of tariffs, which could become a tailwind. Notably, the 2024/25 guidance was maintained and includes headwinds from FX and tariffs. We reiterate our BUY, but have cut our target price to DKK144 (155).

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
Jesper Ingildsen
  • Jesper Ingildsen

Ambu (Buy, TP: DKK155.00) - Another strong quarter

We forecast Ambu to have another strong quarter, with c14% organic growth (we are above consensus) and continued solid margin progression. Despite tariffs, we expect the company to maintain its full-year guidance, but possibly increase the top-line guidance later in the year. We will also look for comments on the impact of tariffs on margins in the coming years. We reiterate our BUY, but have lowered our target price to DKK155 (165).

ResearchPool Subscriptions

Get the most out of your insights

Get in touch